Published on 29 Feb 2024 on Simply Wall St. via Yahoo Finance
An Intrinsic Calculation For Mersana Therapeutics, Inc. (NASDAQ:MRSN) Suggests It's 26% Undervalued
Key Insights
Mersana Therapeutics' estimated fair value is US$6.60 based on 2 Stage Free Cash Flow to EquityMersana Therapeutics is estimated to be 26% undervalued based on current share price of US$4.85 The US$4.80 analyst price target for MRSN is 27% less than our estimate of fair value
Does the February share price for Mersana Therapeutics, Inc. (NASDAQ:MRSN) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by projecting its future cash flows and then discounting them to today's value. This will be done using the Discounted Cash Flow (DCF) model. There's really not all that much to it, even though it might appear quite complex.